TY - JOUR
T1 - New uses of abobotulinumtoxina in aesthetics
AU - Schlessinger, Joel
AU - Gilbert, Erin
AU - Cohen, Joel L.
AU - Kaufman, Joely
N1 - Funding Information:
The authors would like to acknowledge the support of Jane Tricker, freelance writer, who assisted in the writing of this paper, and MedSense, Ltd. (High Wycombe, UK) for editorial support, both funded by Galderma.
Funding Information:
Mentor, Merck, Merz, Novartis, Ortho Pharma. (Johnson & Johnson), Perrigo, Pfizer, Quinnova, Revance, Sandoz, Schering Plough, Tolmar, Valeant, Zydus Cadila, Ulthera, Inc., and Viamet Pharma. Dr Cohen has served as a clinical investigator for Leo, Syneron-Candela, Neothetics, MELA Sciences, Evolus/Alpheon, Suneva, and Croma; and has received honoraria as a clinical investigator/consultant or speaker from Allergan, Valeant, Merz/Ulthera/Cellfina, Galderma, Sciton, and Thermi/Almirall. Dr Kaufman has received research funding from Allergan, grants and research funding from Merz, personal fees and honoraria from Galderma, and research funding from Revance. Dr Gilbert declared no potential conflicts of interest with respect to the research, authorship, and publication of this article.
Funding Information:
This publication was supported by Galderma Laboratories, LP (Fort Worth, TX), who funded the development of this supplement. Editorial assistance was funded by Galderma Laboratories, LP, and provided by Jane Tricker and MedSense, Ltd. (High Wycombe, UK). The authors did not receive compensation for writing the manuscripts.
Publisher Copyright:
© 2017 The American Society for Aesthetic Plastic Surgery, Inc.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2017
Y1 - 2017
N2 - BotulinumtoxinA (BoNT-A) is now widely established for the main approved indication of reducing glabellar lines, and is also widely used off-label to improve the appearance of wrinkles and lines in other parts of the face. The number of aesthetic procedures continues to increase as the patient population becomes more diverse, in particular with increasing numbers of people of color and men. Further developments in treatment may continue to expand the audience for BoNT-A by making procedures more comfortable and by delivering a more natural, less static appearance. These may be achieved through use of combinations of BoNT-A with other aesthetic procedures, tailoring the dose of toxin to the patient's muscle mass or by using novel injection and application techniques. Beyond amelioration of facial lines, encouraging results have been seen with the use of BoNT-A to improve the appearance of hypertrophic and keloid scars and even to prevent them. Studies have been conducted with scars in various parts of the body and further research is ongoing. Dermatological and other medical uses for BoNT-A are also active areas of research. Injections of BoNT-A have been shown to reduce signs and symptoms of acne, rosacea, and psoriasis, to reduce neuromuscular pain, and to bring about significant improvements in a number of rare diseases that are caused or exacerbated by hyperhidrosis. This paper reviews these new uses for BoNT-A, looking at the rationale for their use and discussing the results of published case studies and clinical trials. These areas have shown great promise to date, but more and larger clinical studies will be required before these treatments become a clinical reality. To this end details are also provided of clinical trials currently listed in the main clinical trials database to highlight research areas of particular interest.
AB - BotulinumtoxinA (BoNT-A) is now widely established for the main approved indication of reducing glabellar lines, and is also widely used off-label to improve the appearance of wrinkles and lines in other parts of the face. The number of aesthetic procedures continues to increase as the patient population becomes more diverse, in particular with increasing numbers of people of color and men. Further developments in treatment may continue to expand the audience for BoNT-A by making procedures more comfortable and by delivering a more natural, less static appearance. These may be achieved through use of combinations of BoNT-A with other aesthetic procedures, tailoring the dose of toxin to the patient's muscle mass or by using novel injection and application techniques. Beyond amelioration of facial lines, encouraging results have been seen with the use of BoNT-A to improve the appearance of hypertrophic and keloid scars and even to prevent them. Studies have been conducted with scars in various parts of the body and further research is ongoing. Dermatological and other medical uses for BoNT-A are also active areas of research. Injections of BoNT-A have been shown to reduce signs and symptoms of acne, rosacea, and psoriasis, to reduce neuromuscular pain, and to bring about significant improvements in a number of rare diseases that are caused or exacerbated by hyperhidrosis. This paper reviews these new uses for BoNT-A, looking at the rationale for their use and discussing the results of published case studies and clinical trials. These areas have shown great promise to date, but more and larger clinical studies will be required before these treatments become a clinical reality. To this end details are also provided of clinical trials currently listed in the main clinical trials database to highlight research areas of particular interest.
UR - http://www.scopus.com/inward/record.url?scp=85021857660&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021857660&partnerID=8YFLogxK
U2 - 10.1093/asj/sjx005
DO - 10.1093/asj/sjx005
M3 - Article
C2 - 28388720
AN - SCOPUS:85021857660
VL - 37
SP - S45-S58
JO - Aesthetic Surgery Journal
JF - Aesthetic Surgery Journal
SN - 1090-820X
ER -